Kisho

Warner-Lambert Company — Rare Disease Pipeline | Kisho | Kisho

Warner-Lambert Company

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
T-cell adult acute lymphocytic leukemia	Amsacrine	Orphan Designation	-
adult acute lymphoblastic leukemia	Amsacrine	Orphan Designation	-
adult acute monocytic leukemia	Amsacrine	Orphan Designation	-
amyotrophic lateral sclerosis	gabapentin	Orphan Designation	-
brain cancer	Diaziquone	Orphan Designation	-
brain sarcoma	Diaziquone	Orphan Designation	-
brainstem cancer	Diaziquone	Orphan Designation	-
developmental and epileptic encephalopathy 119	Enadoline hydrochloride	Orphan Designation	-
glioblastoma	Diaziquone	Orphan Designation	-
hormone receptor-positive breast cancer	Suramin	Orphan Designation	-
hormone-resistant breast carcinoma	Suramin	Orphan Designation	-
hormone-resistant prostate carcinoma	Suramin	Orphan Designation	-
microcephalic osteodysplastic primordial dwarfism type I	Cerebyx	Orphan Designation	-
mitochondrial DNA depletion syndrome 13	Cerebyx	Orphan Designation	-
multiple congenital anomalies-hypotonia-seizures syndrome 2	Cerebyx	Orphan Designation	-
neurodevelopmental disorder with hypotonia and speech delay, with or without seizures	Cerebyx	Orphan Designation	-
neurodevelopmental disorder with involuntary movements	Enadoline hydrochloride	Orphan Designation	-
neurodevelopmental disorder with progressive spasticity and brain abnormalities	Cerebyx	Orphan Designation	-
neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities	Cerebyx	Orphan Designation	-
primary brain neoplasm	Diaziquone	Orphan Designation	-
primary central nervous system lymphoma	Diaziquone	Orphan Designation	-